treprostinil subcutaneous depot (CAM2043) / Camurus - LARVOL DELTA

An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in systemic sclerosis-related Raynaud's phenomenon. (PubMed, Rheumatology (Oxford)) - P2 | "The positive outcome indicates that CAM2043 could be further investigated in clinical trials of RP."

Journal • Cardiovascular • Dermatology • Immunology • Pain • Rheumatology • Scleroderma • Systemic Sclerosis

An Exploratory Trial Assessing Finger Perfusion, Raynaud's Condition Score and Safety, Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud's Phenomenon Secondary to Systemic Sclerosis (BSR 2023) - "Finger skin temperature rose after CAM2043 treatment (significantly at 24 hours post-dose), with significant improvements in RP symptoms (RCS) over the 15-day period following dosing indicating a positive treatment effect. Overall, the safety profile for CAM2043 was consistent with known safety profile for treprostinil, including injection site reactions. The results indicate that CAM2043 could be further investigated in clinical trials of RP."

Clinical • Cardiovascular • Dermatology • Fibrosis • Immunology • Pain • Rheumatology • Scleroderma • Systemic Sclerosis